SCHEMBL4840314

SCHEMBL4840314

CN(C)c1ccc(-c2ccc(CCNC(=O)C(CC(=O)NOC(c3ccccc3)(c3ccccc3)c3ccccc3)CC(=O)OC(C)(C)C)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA2 P00918 5/20 0.40
CA9 Q16790 1/20 0.38
USP2 O75604 1/20 0.38
ESRRG P62508 1/20 0.38
MMP2 P08253 5/20 0.37
MMP9 P14780 1/20 0.37
MMP8 P22894 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
MMP3 P08254 3/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
NR1H2 P55055 1/20 0.36
HRH3 Q9Y5N1 1/20 0.35
MMP1 P03956 1/20 0.35
CTSK P43235 2/20 0.34
CA1 P00915 1/20 0.34
CA7 P43166 1/20 0.34
CA14 Q9ULX7 1/20 0.34
CTSS P25774 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4839942 0.93 CA2 (0.45) CA2CA9ESRRGMMP2MMP9
SCHEMBL4840798 0.91 MMP2 (0.45) CA2CA9ESRRGMMP2MMP9
SCHEMBL4841261 0.88 ABCB1 (0.46) CA2CA9ESRRGMMP2MMP9
SCHEMBL4835699 0.86 SMN1; SMN2 (0.43) CA2CA9NPC1RAB9ACA1
SCHEMBL4831392 0.85 CA2 (0.43) CA2CA9ESRRGMMP2MMP9
SCHEMBL4838858 0.85 CA2 (0.39) CA2CA9ESRRGL3MBTL1MMP3
SCHEMBL4831283 0.84 CA2 (0.49) CA2CA9MMP9MMP8L3MBTL1
SCHEMBL4886128 0.83 KMT2A (0.45) CA2CA9USP2MMP2MMP3
SCHEMBL4840333 0.82 CA2 (0.35) CA2CA9USP2L3MBTL1RAB9A
SCHEMBL6253965 0.82 MMEL1 (0.51) CA2CA9ESRRGMMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365091-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2008-04-29 US disclosed
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2006-12-21 US disclosed
US-7105539-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-09-12 US disclosed
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-06-22 US disclosed
EP-1572645-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX Enobia Pharma Inc. (CA) 2005-09-14 EP disclosed
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex BIOMEP INC. 2004-09-23 US disclosed
WO-2004050620-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX ENOBIA PHARMA (CA) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX GLS, SUCNR1, PGD CA2 333/4885CA9 776/4885USP2 2926/4885
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, PGD CA2 344/4885CA9 841/4885USP2 3011/4885
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, GCDH CA2 366/4885CA9 783/4885USP2 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.